259 related articles for article (PubMed ID: 34646378)
1. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform.
Xing F; Liu YC; Huang S; Lyu X; Su SM; Chan UI; Wu PC; Yan Y; Ai N; Li J; Zhao M; Rajendran BK; Liu J; Shao F; Sun H; Choi TK; Zhu W; Luo G; Liu S; Xu L; Chan KL; Zhao Q; Miao K; Luo KQ; Ge W; Xu X; Wang G; Liu TM; Deng CX
Theranostics; 2021; 11(19):9415-9430. PubMed ID: 34646378
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
Mäkelä R; Arjonen A; Härmä V; Rintanen N; Paasonen L; Paprotka T; Rönsch K; Kuopio T; Kononen J; Rantala JK
BMC Cancer; 2020 Jun; 20(1):590. PubMed ID: 32576176
[TBL] [Abstract][Full Text] [Related]
3. RNAi High-Throughput Screening of Single- and Multi-Cell-Type Tumor Spheroids: A Comprehensive Analysis in Two and Three Dimensions.
Fu J; Fernandez D; Ferrer M; Titus SA; Buehler E; Lal-Nag MA
SLAS Discov; 2017 Jun; 22(5):525-536. PubMed ID: 28277887
[TBL] [Abstract][Full Text] [Related]
4. Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen.
Walsh AJ; Cook RS; Skala MC
J Nucl Med; 2017 Sep; 58(9):1367-1372. PubMed ID: 28588148
[TBL] [Abstract][Full Text] [Related]
5. Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening.
Hou S; Tiriac H; Sridharan BP; Scampavia L; Madoux F; Seldin J; Souza GR; Watson D; Tuveson D; Spicer TP
SLAS Discov; 2018 Jul; 23(6):574-584. PubMed ID: 29673279
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening with nanoimprinting 3D culture for efficient drug development by mimicking the tumor environment.
Yoshii Y; Furukawa T; Waki A; Okuyama H; Inoue M; Itoh M; Zhang MR; Wakizaka H; Sogawa C; Kiyono Y; Yoshii H; Fujibayashi Y; Saga T
Biomaterials; 2015 May; 51():278-289. PubMed ID: 25771018
[TBL] [Abstract][Full Text] [Related]
7. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
8. In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients.
Al-Samadi A; Poor B; Tuomainen K; Liu V; Hyytiäinen A; Suleymanova I; Mesimaki K; Wilkman T; Mäkitie A; Saavalainen P; Salo T
Exp Cell Res; 2019 Oct; 383(2):111508. PubMed ID: 31356815
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiologically relevant in vitro tumor models for drug screening.
Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
[TBL] [Abstract][Full Text] [Related]
10. Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures.
Mosaad E; Chambers K; Futrega K; Clements J; Doran MR
BMC Cancer; 2018 May; 18(1):592. PubMed ID: 29793440
[TBL] [Abstract][Full Text] [Related]
11. Real-Time Apoptosis and Viability High-Throughput Screening of 3D Multicellular Tumor Spheroids Using the Celigo Image Cytometer.
Kessel S; Cribbes S; Bonasu S; Qiu J; Chan LL
SLAS Discov; 2018 Feb; 23(2):202-210. PubMed ID: 28915356
[TBL] [Abstract][Full Text] [Related]
12. Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening.
Krausz E; de Hoogt R; Gustin E; Cornelissen F; Grand-Perret T; Janssen L; Vloemans N; Wuyts D; Frans S; Axel A; Peeters PJ; Hall B; Cik M
J Biomol Screen; 2013 Jan; 18(1):54-66. PubMed ID: 22923784
[TBL] [Abstract][Full Text] [Related]
13. 3D Culture as a Clinically Relevant Model for Personalized Medicine.
Fong ELS; Toh TB; Yu H; Chow EK
SLAS Technol; 2017 Jun; 22(3):245-253. PubMed ID: 28277923
[TBL] [Abstract][Full Text] [Related]
14. The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform.
Mosaad EO; Chambers KF; Futrega K; Clements JA; Doran MR
Sci Rep; 2018 Jan; 8(1):253. PubMed ID: 29321576
[TBL] [Abstract][Full Text] [Related]
15. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
Powley IR; Patel M; Miles G; Pringle H; Howells L; Thomas A; Kettleborough C; Bryans J; Hammonds T; MacFarlane M; Pritchard C
Br J Cancer; 2020 Mar; 122(6):735-744. PubMed ID: 31894140
[TBL] [Abstract][Full Text] [Related]
17. 3-Dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems.
Howes AL; Richardson RD; Finlay D; Vuori K
PLoS One; 2014; 9(9):e108283. PubMed ID: 25247711
[TBL] [Abstract][Full Text] [Related]
18. Zebrafish Xenografts for Drug Discovery and Personalized Medicine.
Xiao J; Glasgow E; Agarwal S
Trends Cancer; 2020 Jul; 6(7):569-579. PubMed ID: 32312681
[TBL] [Abstract][Full Text] [Related]
19. Deconvolution of cell type-specific drug responses in human tumor tissue with single-cell RNA-seq.
Zhao W; Dovas A; Spinazzi EF; Levitin HM; Banu MA; Upadhyayula P; Sudhakar T; Marie T; Otten ML; Sisti MB; Bruce JN; Canoll P; Sims PA
Genome Med; 2021 May; 13(1):82. PubMed ID: 33975634
[TBL] [Abstract][Full Text] [Related]
20. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
